Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sosei Group To Revise Strategy And Reduce R&D Expenses

This article was originally published in PharmAsia News

Executive Summary

Tokyo-based biopharmaceutical company Sosei Group announced May 14 forecasts for fiscal year 2008 and a review of its strategy. Net sales is estimated to be ¥190 million and income will be at a loss of ¥3.18 billion. In R&D expenses, compared to nearly ¥4 billion in fiscal year 2007, it is estimated to be ¥900 million for FY 2008. Sosei will maintain the rights to NVA237/QVA149 that were in-licensed from Novartis, but will seek to out-license or sell all other assets generated in the U.K. including AD923, a cancer breakthrough pain drug. The company will no longer operate a drug discovery unit but will continue to develop in-house neuropathic pain drug SD118 and emergency contraceptive SHO-175. (Click here for more - Japanese language)

Related Content

Sosei’s Emergency Contraceptive Effective In Phase III



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts